HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RU 58668

a steroidal antiestrogen; induces a long-term regression of human mammary MCF-7 tumors implanted in nude mice; structure given in first source

Also Known As:

11beta-(4-(5-((4,4,5,5,5-pentafluoropentyl)sulfonyl)pentyloxy)phenyl)-estra-1,3,5(10)-triene,3,17beta-diol; Estra-1,3,5(10)-triene-3,17-diol, 11-(4-((5-((4,4,5,5,5-pentafluoropentyl)sulfonyl)pentyl)oxy)phenyl)-, (11beta,17beta)-; RU 58 668; RU-58668

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Connault, Elisabeth: 1 article (07/2006)
2.	Fattal, Elias: 1 article (07/2006)
3.	Gauduchon, Juliette: 1 article (07/2006)
4.	Gouilleux, Fabrice: 1 article (07/2006)
5.	Maillard, Sébastien: 1 article (07/2006)
6.	Marsaud, Véronique: 1 article (07/2006)
7.	Opolon, Paule: 1 article (07/2006)
8.	Renoir, Jack-Michel: 1 article (07/2006)
9.	Sola, Brigitte: 1 article (07/2006)

Related Diseases

1.	Neoplasms (Cancer) 06/12/1995 - "So the first purpose of this work was to study the effect of RU 58668 for 6 months and to evaluate its activity on tumors which escaped from the tamoxifen treatment. " 06/12/1995 - "Long-term studies of RU 58668 on the estradiol-stimulated MCF-7 model showed that this compound induced a shrinking of tumor volumes for at least 25 weeks (3 to 6 times longer than the stabilization induced by tamoxifen) and was able to reduce the volume of tumors which escaped from, or even were stimulated by, tamoxifen. " 06/12/1995 - "On models of spontaneously growing tumors, where the overexpression of an oncogene or the production of growth factors was involved, RU 58668 induced the same tumor shrinking that was previously observed on estradiol- or tamoxifen-stimulated models. "
2.	Breast Neoplasms (Breast Cancer) 12/01/1996 - "Taken together, these results suggest a promising usefulness for RU 58668 in the treatment of metastatic breast cancer in women." 01/01/1996 - "Most of the work with RU 58668 has focused on its potential as an antineoplastic agent in the treatment of breast cancer, but it has not been tested for its effects on the brain and behavior. " 06/12/1995 - "Exploration of the therapeutic potential of the antiestrogen RU 58668 in breast cancer treatment." 01/15/1998 - "OHT partially counteracts the larger growth inhibition of human breast cancer cells exerted by the steroidal antiestrogens ICI 182780 and RU 58668. " 04/01/1999 - "In MCF-7 breast cancer cells, estradiol (E2) and pure antiestrogen RU 58668 down-regulate the estrogen receptor (ER). "
3.	Multiple Myeloma 07/01/2006 - "In most of multiple myeloma (MM) cells, the "pure" antiestrogen (AE) RU 58668 (RU) induced either a G1-arrest (LP-1, OPM-2, NCI-H929, U266 cells) or apoptosis (RPMI 8226 cells). "
4.	Body Weight (Weight, Body) 01/01/1996 - "Our results show that RU 58668 blocked estrogen's suppressive effects on feeding behavior and body weight. " 01/01/1996 - "Therefore, RU 58668 is the first antiestrogen that blocks estradiol's effects on female sexual behavior while also inhibiting estradiol's effects on feeding behavior and body weight."

Related Drugs and Biologics

1.	Estradiol (Delestrogen)
2.	Tamoxifen
3.	Estrogen Receptor Modulators (Antiestrogen)
4.	Estrogen Receptors
5.	Intercellular Signaling Peptides and Proteins (Growth Factors)
6.	Estrogens (Estrogen)
7.	Antineoplastic Agents (Antineoplastics)
8.	Fulvestrant (Faslodex)